Timothy C. Evans

Jefferies & Company analysts David Windley, Timothy C. Evans and Andrew Hilgenbrink reiterated their Buy rating for shares of Pharmaceutical Product Development Inc (Nasdaq: PPDI), with a price target of $32 per share. The analysts said that Pharmaceutical Product Development Inc management has...